CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2019-12-31
2018-12-31
2017-12-31
2016-12-31
Total Revenue
897
1,193
2,428
2,045
589
Operating Expenses
Research Development
48,113
41,506
24,479
9,233
5,100
Selling General and Administrative
14,354
13,519
6,659
1,939
1,533
Total Operating Expenses
62,467
55,025
31,138
11,172
6,633
Operating Income or Loss
-61,570
-53,832
-28,710
-9,127
-6,044
Interest Expense
-
-
0
8
11
Total Other Income/Expenses Net
-202
-50
-153
-48
-1
Income Before Tax
-58,766
-50,422
-27,115
-9,157
-6,019
Income from Continuing Operations
-58,766
-50,422
-27,115
-9,157
-6,019
Net Income
-58,766
-50,422
-27,115
-9,157
-6,019
Net Income available to common shareholders
-58,766
-50,422
-27,115
-9,157
-6,019
Basic EPS
-
-2.09
-2.23
-1.18
-0.43
Diluted EPS
-
-2.09
-2.23
-1.18
-0.43
Basic Average Shares
-
24,175
12,142
7,746
13,878
Diluted Average Shares
-
24,175
12,142
7,746
13,878
EBITDA
-
-52,945
-26,644
-9,021
-5,916